PrismRA For Physicians

PrismRA Delivers Precision Medicine to You and Your Patients with Rheumatoid Arthritis

PrismRA is a blood-based, precision medicine, molecular signature response classifier (MSRC) that predicts inadequate response to TNFi therapy in rheumatoid arthritis.

Download a summary of PrismRA clinical utility studies

90% Positive Predictive Value

PrismRA delivers proven, data-driven, precision medicine validated to predict TNFi inadequate response.

Rheumatologists Are Forced to Take a Trial-and-Error Approach to Therapy Selection

Up to 90 percent

of patients with RA are treated with TNFi therapies as first-line biologic or targeted synthetic DMARD3,4

Only About One-Third

of patients with RA reach ACR50 at 6 months with b/tsDMARD after failing methotrexate5,6

Knowing the patient’s PrismRA score helps guide decision making to stop the current trial-and-error approach

The PrismRA Molecular Signature Response Classifier Was Developed to Guide Therapy Selection

To develop PrismRA, Scipher started with approximately 7,000 biological features. Using artificial intelligence, we identified and ranked the top 23 features most predictive of inadequate response to TNFi therapies.

Gene Expression Features
Scipher Medicine

Therapeutic Response Is Predicted by Capturing the Interaction between All 23 Features NOT by Any Single Feature

Neural Network Model

PrismRA Neural Network Model

An Actionable, Easy to Interpret, Single Page Result to Guide Therapy Selection

    • The PrismRA result shows whether a TNFi inadequate response signature is detected.
    • The PrismRA score is reported on a scale of 1 to 25. The higher the score, the more likely the patient is to have an inadequate response to TNFi therapies.
    • Based on the PrismRA score, PrismRA predicts your patient’s probability of response to TNFi therapy.

    Download Sample Report

    PrismRA Provides Unique Insights to Guide Treatment Decisions

    TNFi High Signal Chart

    >10.6 is a high signal of inadequate response and the patient has a 10% chance of responding to a TNFi

    TNFi Very High Signal Chart

    >18.5 is a very high signal of
    inadequate response and the patient has a 5% chance of responding to a TNFi

    TNFi No Signal Chart

    <10.6 indicates that no signal of inadequate response was detected and the patient may be likely to respond to a TNFi*

    *A low PrismRA score does not ensure a positive response.

    Ordering PrismRA Is Easy

    Icon of Nurse - Step 1

    Identify a patient that would benefit from PrismRA

    Step 2 - Icon of Test Tube

    Fill out the single-page test requisition form (TRF) with your patient’s information

    Step 3 - Icon of truck

    Complete a blood draw in your clinic or via our collection services

    Step 4 - Icon of Chart

    Package everything in the PrismRA Kit and ship to Scipher with the included prepaid labels

    Step 5 - Icon of Caduceus

    Receive the PrismRA result within 5-7 business days and select therapy based on your patient’s unique biology

    Publications and Abstracts

    Learn More About PrismRA

    Interested in how PrismRA helps guide therapy decisions? Please contact the Scipher Medicine Client Services team.


    Phone Icon855-724-7437

    1. Jones A, et al. Expert Rev Mol Diagn. 2021;21(11):1235-1243. 2. Strand V, et al. Expert Rev Mol Diagn. 2022;22(1):101-109. 3. Jin Y, et al. Arthritis Res Ther. 2017;19(1):159.
    4. Curtis Jr, et al. Arthritis Care Res (Hoboken). 2014;66(11):1604-11. 5. Incerti, D, Jansen, JP. A Description of the IVI-RA Model v2.0. 2020; last updated January 2020. 6. Curtis JR, et al. Semin Arthritis Rheum. 2010;40(1):2-14.